---
document_datetime: 2025-10-07 11:34:57
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/daxas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: daxas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4970693
conversion_datetime: 2025-12-30 01:45:57.288778
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Daxas

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber      | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA_IN / | A.5Changeinthenameand/oraddressofa | 06/10/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000303126   | manufacturer/importer of the finished product (including batch release or quality controltestingsites)-A.5.aTheactivities for which the manufacturer/importer is responsibleincludebatchrelease-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     | PL   |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-------------------|
| Variation type IB / | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the risk management plan - C.I.11.z Change in due dateforcategory1,2or3studiesinthe RMP and/orAnnexII-Refused C.I.11.z (Type IB) - to provide an updated RMPbasedonthefinaloutcomesofthe completedprocedurefornon-interventional Post-AuthorisationSafetyStudy (D7120R00003),Long-termpost-marketing observationalstudyof thesafetyof roflumilastassessedwithprocedure EMEA/H/C/PSR/S/0041.TheamendedRMP includedthereclassification andremoval of safetyconcernsalsorecommendedaspart ofthefinalAssessmentReportforprocedure EMEA/H/C/PSUSA/00002658/202401. | 05/06/2025 | N/A |      | EMA/VR/0000256542 |